West Nile Virus Europe 2026: Record Cases Alarm ECDC
West Nile virus Europe 2026: ECDC reports 1,715 locally acquired EU cases and 130 deaths as of 7 October. What the data show and what to do.
Labcorp BioReference Acquisition: Bold Up-to-$872M Deal
Labcorp BioReference acquisition: $722M cash plus up to $150M for select OPKO assets and the 4Kscore test. Terms, assets, caveats and open questions.
Rasonque EMA Recommendation: Promising Survival Gains
Rasonque EMA recommendation: the CHMP backs the oral RAS inhibitor for pretreated metastatic pancreatic cancer. Survival data, side effects, next steps.
AstraZeneca insitro AI Drug Discovery Deal: Bold $1.5B Bet
The AstraZeneca insitro AI drug discovery deal: $40M upfront, up to ~$1.46B in milestones, for MASH and heart disease. What is certain and what is not.
Sri Lanka Pharmaceutical Manufacturing: Bold $20M Push
Sri Lanka pharmaceutical manufacturing gets a Zydus-Sunshine plant in Horana: over $20M planned, operations from 2028. What is known and still unclear.
Celiac Disease Treatment: Promising ANB033 Gut Data
A celiac disease treatment candidate, ANB033, limited gluten-linked gut damage and symptoms in a 32-patient trial. Early data from a small study.
Vir Biotechnology Partnership: Bold $1.88B Gilead Deal
Vir Biotechnology partnership with Gilead is worth up to $1.88B, with $90M upfront, for three solid-tumour T-cell engagers. Terms, science and risks.
Indian Pharmaceutical Market Grows 17.1%: Strong Surge
Indian pharmaceutical market sales hit about Rs 25,276 crore in September 2026, up 17.1%, with chronic therapies leading. Why a second dataset shows less.
AstraZeneca India Clinical Trial Partnership: Bold Push
AstraZeneca India clinical trial partnership with NIPER Raebareli targets 25 emerging sites beyond the metros under Biopharma SHAKTI. What is and is not known.
Coronary Stent Safety India: Urgent Probe Ordered
Coronary stent safety India: the Cabinet Secretariat has asked the Health Ministry to examine stent safety and regulation after Sri Lanka withdrawals.